A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) (opens ClinicalTrials.gov)
- Sponsor
- GlaxoSmithKline
- Enrolment
- 610
- Started
- 2026-09-24
- Last update
- 2026-11-03
Conditions: Neoplasms, Endometrial
Interventions: Mocertatug rezetecan, Dostarlimab, Pembrolizumab